MET and non-small cell lung carcinoma: In the present study, we also observed that ricolinostat could increase the crizotinib sensitivity of NSCLC cells (HCC827 and H661) with the high level of c-MET expression, but not NSCLC cells (H1650 and A549) with the low level of c-MET expression (Figure S9).